Therapy for older AML patients: The role of novel agents and allogeneic stem cell transplant

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 10, 2008, Pages 1017-1025

  Lancet, Jeffrey E ^a   Giralt, Sergio ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; Chemotherapy; Elderly patients; Targeted therapy

Indexed keywords

ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; CLOFARABINE; CYTARABINE; DAUNORUBICIN; ENZYME INHIBITOR; FARNESYLTRANFERASE INHIBITOR; FMS LIKE TYROSINE KINASE 3 INHIBITOR; GEMTUZUMAB OZOGAMICIN; HEAT SHOCK PROTEIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BCL 2 INHIBITOR; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TIPIFARNIB; UNCLASSIFIED DRUG; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTILEUKEMIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER MORTALITY; CLINICAL TRIAL; COMORBIDITY; CYTOGENETICS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; GENETIC IDENTIFICATION; GERIATRIC PATIENT; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; MORBIDITY; OUTCOME ASSESSMENT; PERFORMANCE; PROGNOSIS; PROTEOMICS; QUALITY OF LIFE; REDUCED INTENSITY CONDITIONING; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 57549113737     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0077     Document Type: Article

References (71)

1. Surveillance, Epidemiology, and End Results (SEER) Program. Acute myeloid leukemia incidence for 2000-2004. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. 2007. Available at: www.seer.cancer.gov. Accessed September 8, 2008.
2. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-3485.
3. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006;108:63-73. 4 Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006;108:3280-3288.
4. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-1320.
5. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-3329.
6. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/ P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood 1999;94:1086-1099.
7. Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 2004;104:1940-1951.
8. Kantarjian H, O Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090-1098.
9. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1302-1311.
10. Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998;16:872-881.
11. Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997;90:2952-2961.
12. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-485.
13. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995;332:1671-1677.
14. Schoch C, Kern W, Schnittger S, et al. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 2004;89:1082-1090.
15. Cripe LD, Li X, Litzow M, et al. A randomized, placebo-controlled, double blind trial of the MDR modulator, zosuquidar, during conventional induction and post-remission therapy for pts >60 years of age with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): ECOG 3999 [abstract]. Blood 2006;108:Abstract 423.
16. Lancet J, Baer MR, Cripe LD, et al. Phase I/II pharmacodynamic study of the P-glycoprotein (Pgp) inhibitor zosuquidar administered by continuous infusion (CIV) with daunorubicin (DNR) and cytarabine (ARA-C) as primary therapy in older patients with acute myeloid leukemia (AML) [abstract]. Blood 2006;108:Abstract 422.
17. Burnett AK, Baccarani M, Johnson P, et al. Clofarabine in previously untreated elderly (>65 yrs) AML patients with an unfavourable cytogenetic profile who are considered unfit for standard intensive chemotherapy [abstract]. J Clin Oncol 2006;24:Abstract 6513.
18. Giles F, Rizzieri D, Karp J, et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 2007;25:25-31.
19. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-57.
20. Silverman LR, Demakos EP, Peterson BL, et al. randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429-2440.
21. Lubbert M, Ruter B, Claus R, et al. Continued low-dose decitabine (DAC) is an active first-line treatment in all cytogenetic subgroups of older AML patients: results of the FR00331 multicenter phase II study [abstract]. Blood 2007;110:Abstract 300.
22. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-3279.
23. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25:3884-3891.
24. Garcia-Manero G, Yang AS, Klimek V, et al. Phase I/II study of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) [abstract]. Blood 2007;110:Abstract 444.
25. Grovdal M, Khan R, Aggerholm A, et al. Maintenance treatment with azacytidine for patients with high risk myelodysplastic syndromes or acute myeloid leukaemia in complete remission after intensive chemotherapy [abstract]. Blood 2007;110:Abstract 818.
26. Lancer JE, Gojo I, Gotlib J, et al. A phase II study of the farnesyl-transferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2007; 109:1387-1394.
27. Harousseau JL, Martinelli G, Jedrzejczak WW, et al. A randomized phase 3 study of tipifarnib compared to best supportive care (including hydroxyurea) in the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 70 years or older [abstract]. Blood 2007;110:Abstract 439.
28. Raponi M, Lancet JE, Fan H, et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008;111:2589-2596.
29. Karp JE, Smith BD, Gojo I, et al. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res 2008;14:3077-3082.
30. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-1542.
31. DeAngelo DJ, Stone RM, Heaney ML, et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 2006;108:3674-3681.
32. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108:3262-3270.
33. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54-60.
34. DeAngelo DJ, Amrein PC, Kovacsovics TJ, et al. Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML) [abstract]. Blood 2006;108:Abstract 158.
35. Stone RM, Fischer T, Paquette R, et al. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under age 61 [abstract]. Blood 2006;108:Abstract 157.
36. Stone RM, Klimek V, DeAngelo DJ, et al. PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): a phase II clinical trial [abstract]. Blood 2002;100:Abstract 86a.
37. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005;104:1442-1452.
38. Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia 2006;21:66-71.
39. Amadori S, Suciu S, Willemze R, et al. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 2004;89:950-956.
40. Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002;99:4343-4349.
41. Fianchi L, Pagano L, Leoni F, et al. Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. Ann Oncol 2008;19:128-134.
42. Harousseau JL, Recher CFR, Vey N, et al. Gentuzumab-ozogamicin (GO) plus idarubicin (I) and cytarabine (C) as induction treatment for elderly patients with poor-risk cytogenetics acute myeloid leukemia (AML) [abstract]. Blood 2007;110:Abstract 1839.
43. Piccaluga PP, Martinelli G, Rondoni M, et al. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res 2004;28:987-990.
44. Armitage J. Bone marrow transplantation. N Engl J Med 1994; 330:827-838.
45. Loberiza F. Report on the state of the art in blood and marrow transplantation. Part 1 of the IBMTR/ABMTR summary slides with guide. IBMTR/ABMTR Newsletter 2003;10:7-10.
46. Frassoni F, Labopin M, Arcese W, et al. The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for AML 1CR is significantly worse after 35 years. Implication for reducing the intensity of the conditioning regimen. Report of the acute leukemia working party of EBMT [abstract]. Blood 2000;96:Abstract 393a.
47. Ringden O, Horowitz M, Gale R, et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993;270:57-60.
48. Gale R, Bortin M, Van Bekkum D, et al. Risk factors for acute graft versus host disease Br J Haematol 1987;67:397-400.
49. Ferrara J, Deeg H. Graft versus host disease. N Engl J Med 1991; 324:667-674.
50. Horowitz M, Loberiza F, Bredeson C, Nugent M. Transplant registries: guiding clinical decisions and improving outcomes. Oncology 2001:15:649-659.
51. Wallen H, Gooley TG, Deeg HJ, et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005;23:3439-3446.
52. Ditschkowski M, Elmaagacli AH, Trenschel R, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients. Clin Transplant 2006;20:127-131.
53. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft versus-leukemia without myeloablative therapy. Blood 1997;89:4531-4536.
54. Slavin S, Nagler A, Naparstak E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood 1998;91:756-763.
55. Khouri I, Keating MJ, Korbling M, et al. Transplant lite: induction of graft vs malignancy using fludarabine based nonablative chemotherapy and allogeneic progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824.
56. Champlin R, Khouri I, Kornblau J, et al. Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft versus malignancy effect. Oncology 1999;13:621-626.
57. McSweeney P, Niederwieser D, Shizuru J, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-3400.
58. Kiss TL, Sabry W, Lazarus HM, Lipton JH. Blood and marrow transplantation in elderly acute myeloid leukemia patients-older certainly is not better. Bone Marrow Transplant 2007;40:405-415.
59. Center for International Blood & Marrow Transplant Research. Summary Slides. Available at: www.cibmtr.org/SERVICES/Observational_Research/ Summary_Slides. Accessed September 8, 2008.
60. Wong R, Giralt S, Martin T, et al. Reduced intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003;102:3052-3059.
61. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced intensity conditioning regimens in the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome: dose is relevant for long term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004;104:865-872.
62. Gupta V, Daly A, Lipton J, et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 2005;11:764-772. 64 Tauro S, Craddock C, Peggs K, et al. Allogeneic stem cell transplantation using a reduced intensity conditioning regimen has the capacity to produce durable remissions and ling term disease free survival in patients with high risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005;23:9387-9393.
63. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for patients older than 50 years with acute myeloblastic leukemia: a retrospective survey from the acute leukemia working party of the European group for blood and marrow transplantation. Leukemia 2005;19:2304-2312.
64. Hegenbart U, Nierderwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low dose TBI based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006;24:444-453.
65. Popat U, Heslop HE, Durett A, et al. Outcome of reduced intensity allogeneic hematopoietic stem cell transplantation using antilymphocyte antibodies in patients with high risk acute myeloid leukemia. Bone Marrow Transplant 2006;37:547-552.
66. Kroger N, Shimoni A, Zabelina T, et al. Reduced toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation in elderly patients with secondary acute myeloid leukemia or myelodysplastic syndrome. Bone Marrow Transplant 2006;37:339-344.
67. Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced intensity conditioning regimens for hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Blood 2007;109:1395-1400.
68. Shimoni A, Kroger N, Zabelina T, et al. Hematopoietic stem cell transplantation from unrelated donors in elderly patients (age > 55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 2005; 19:7-12.
69. Falda M, Busca A, Baldi I, et al. Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Mjdollo Osseo) multicenter prospective trial. Am J Hematol 2007; 82:863-866.
70. Sorror M, Storer B, Sandmaier B, et al. Hematopoietic cell transplantation comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008;112;1992-2001.
71. Majhail N, Brunstein C, Tomblyn M, et al. Reduced intensity allogeneic transplant in patients older than 55 years of age. Unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Trans 2008;14:282-289.